LT3130347T - Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas - Google Patents

Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas

Info

Publication number
LT3130347T
LT3130347T LT16189970T LT16189970T LT3130347T LT 3130347 T LT3130347 T LT 3130347T LT 16189970 T LT16189970 T LT 16189970T LT 16189970 T LT16189970 T LT 16189970T LT 3130347 T LT3130347 T LT 3130347T
Authority
LT
Lithuania
Prior art keywords
formulations
polypeptide variants
polypeptide
variants
Prior art date
Application number
LT16189970T
Other languages
English (en)
Lithuanian (lt)
Inventor
Ge Wei
H Shepard
Qiping Zhao
Robert James Connor
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47595052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3130347(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of LT3130347T publication Critical patent/LT3130347T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • G01N2333/928—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
LT16189970T 2011-12-30 2012-12-28 Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas LT3130347T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161631313P 2011-12-30 2011-12-30
US201261796208P 2012-11-01 2012-11-01

Publications (1)

Publication Number Publication Date
LT3130347T true LT3130347T (lt) 2019-10-25

Family

ID=47595052

Family Applications (1)

Application Number Title Priority Date Filing Date
LT16189970T LT3130347T (lt) 2011-12-30 2012-12-28 Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas

Country Status (23)

Country Link
US (28) US9447401B2 (enExample)
EP (2) EP3130347B1 (enExample)
JP (2) JP6067746B2 (enExample)
CN (1) CN104244968B (enExample)
AU (2) AU2012362141B2 (enExample)
BR (1) BR112014016195A2 (enExample)
CA (1) CA2861919C (enExample)
CY (1) CY1122532T1 (enExample)
DK (2) DK2797622T3 (enExample)
EA (1) EA030252B9 (enExample)
ES (2) ES2609582T3 (enExample)
HR (1) HRP20192249T1 (enExample)
HU (1) HUE047849T2 (enExample)
IL (5) IL317266A (enExample)
LT (1) LT3130347T (enExample)
MX (2) MX361727B (enExample)
PL (1) PL3130347T3 (enExample)
PT (1) PT3130347T (enExample)
RS (1) RS59703B1 (enExample)
SG (2) SG10201604470TA (enExample)
SI (1) SI3130347T1 (enExample)
SM (1) SMT201900630T1 (enExample)
WO (1) WO2013102144A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EA036569B1 (ru) * 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
HRP20160530T1 (hr) 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
CN105797140B (zh) * 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
KR101828828B1 (ko) 2011-10-24 2018-03-29 할로자임, 아이엔씨 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
HUP1300646A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103819578B (zh) * 2013-11-22 2016-05-11 青岛九龙生物医药有限公司 一种加氢氧化钠法提高硫酸软骨素收率的方法
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20150328317A1 (en) * 2014-05-13 2015-11-19 Eagle Pharmaceuticals, Inc. Aqueous buffer-free bivalirudin compositions
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
HK1252425A1 (zh) 2015-06-05 2019-05-24 Vertex Pharmaceuticals Incorporated 用於治疗脱髓鞘疾病的三唑类药物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
CN105727267B (zh) * 2016-02-05 2020-05-26 苏州康聚生物科技有限公司 一种重组人透明质酸酶冻干制剂及其制备方法和应用
GB201607918D0 (en) * 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
WO2018001430A1 (en) * 2016-06-29 2018-01-04 Science Ventures Denmark A/S A supercapacitor and a method for expanding the voltage range of an aqueous electrolyte supercapacitor
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018222787A1 (en) 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US12371683B2 (en) * 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
CN120053667A (zh) * 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CA3137324A1 (en) * 2020-01-23 2021-07-29 Alteogen, Inc. Novel hyaluronidase variants with improved stability and pharmaceutical composition containing the same
CN111233979A (zh) * 2020-02-19 2020-06-05 四川大学华西医院 一种双子型两亲性短肽及其作为疏水性药物载体的应用
TWI788188B (zh) * 2020-06-09 2022-12-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
TWI881239B (zh) * 2020-06-09 2025-04-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
TWI781415B (zh) * 2020-06-09 2022-10-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법
EP4194551A4 (en) 2020-08-07 2024-08-28 Alteogen, Inc. PROCESS FOR PRODUCING RECOMBINANT HYALURONIDASE
CA3188236A1 (en) 2020-09-14 2022-03-17 Boehringer Ingelheim International Gmbh Heterologous prime boost vaccine
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN112763610B (zh) * 2020-12-28 2022-04-01 浙江大学 土壤中抗生素的检测方法
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
CN112359027B (zh) 2021-01-13 2021-04-13 凯莱英生命科学技术(天津)有限公司 细胞色素p450酶突变体及其应用
CN114350691B (zh) * 2021-03-05 2023-12-08 华熙生物科技股份有限公司 一种高效表达透明质酸水解酶的基因及其表达方法
CN113444708B (zh) * 2021-07-19 2024-02-13 河南赛培生物科技有限公司 一种用于药物皮下注射制剂的透明质酸酶突变体
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
CN117897172A (zh) 2021-08-02 2024-04-16 阿根思有限公司 皮下单位剂型
CA3232451A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
WO2023067008A1 (en) * 2021-10-19 2023-04-27 Pharmact Holding Ag A production of a purified modified bacterial hyaluronidase polypeptide, pharmaceutical compositions and their uses
WO2023075506A1 (ko) * 2021-10-29 2023-05-04 (주)알테오젠 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물
CN114634920B (zh) * 2022-03-24 2024-02-27 江南大学 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
CN114624366B (zh) * 2022-05-16 2022-07-26 南京瑞克卫生物医药有限公司 一种醋酸西曲瑞克聚合物杂质的检测方法
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
PE20252239A1 (es) 2022-12-22 2025-09-15 Halozyme Inc Formulaciones de enzimas hialuronidasa para administracion de alto volumen
EP4680285A1 (en) 2023-03-13 2026-01-21 Heidelberg Pharma Research GmbH Subcutaneously administered antibody-drug conjugates for use in cancer treatment
CN116272708B (zh) * 2023-03-16 2023-11-14 海南医学院 一种量子点-抗体复合物微球及其制备方法、应用
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025168089A1 (zh) 2024-02-08 2025-08-14 上海宝济药业股份有限公司 用于皮下给药的药物组合及其应用
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025248465A1 (en) 2024-05-29 2025-12-04 Janssen Biotech, Inc. Treatment of locally advanced or metastatic egfr-mutated non-small cell lung cancer
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026022739A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022733A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
CN120400103B (zh) * 2025-04-25 2026-02-03 上海齐鲁制药研究中心有限公司 新型ph20突变体酶

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
EP0040472B1 (en) 1980-05-20 1986-01-29 Mallinckrodt, Inc. (a Delaware corporation) Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof
AU546785B2 (en) * 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2085297T3 (es) 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
ATE193551T1 (de) 1991-03-18 2000-06-15 Scripps Research Inst Oligosaccharide als enzymsubstrate und - inhibitoren: verfahren und zusammensetzungen
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5766581A (en) 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US20010055563A1 (en) 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US6461863B1 (en) 1996-08-16 2002-10-08 University Of Wyoming Modifying insect cell gylcosylation pathways with baculovirus expression vectors
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
GB9803751D0 (en) 1998-02-23 1998-04-15 Smithkline Beecham Plc Novel compounds
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
CN1314992A (zh) 1998-07-03 2001-09-26 奈勒斯菲尔德控制有限公司 流体测量的方法和装置
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
MXPA02006216A (es) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Derivados estericamente impedidos de polimeros solubles en agua.
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
US6615063B1 (en) * 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CA2788505C (en) 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US8906363B2 (en) * 2003-05-16 2014-12-09 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
JP2007500508A (ja) 2003-07-29 2007-01-18 モルフォテック、インク． 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005042753A1 (en) 2003-10-28 2005-05-12 Chesapeake Perl, Inc. Production of human glycosylated proteins in transgenic insects
ATE468356T1 (de) 2003-11-25 2010-06-15 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US7112687B2 (en) 2004-07-15 2006-09-26 Indena, S.P.A. Methods for obtaining paclitaxel from taxus plants
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP5201572B2 (ja) 2005-06-09 2013-06-05 ナノキャリア株式会社 白金錯体のポリマー化配位化合物の製造方法
JP2007153797A (ja) * 2005-12-05 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
CN104650213A (zh) 2006-08-01 2015-05-27 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
US8288142B2 (en) 2007-06-19 2012-10-16 Uvarkina Tamara P Hyaluronidase and method of use thereof
EP4269578B8 (en) 2008-03-06 2024-07-17 Halozyme, Inc. Soluble hyaluronidase composition
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EA036569B1 (ru) * 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
HRP20160530T1 (hr) * 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
JP5136582B2 (ja) 2010-03-24 2013-02-06 ブラザー工業株式会社 現像カートリッジ
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
US8401194B2 (en) * 2010-10-15 2013-03-19 Roche Diagnostics Operations, Inc. Diabetes care kit that is preconfigured to establish a secure bidirectional communication link between a blood glucose meter and insulin pump
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
US9149160B2 (en) 2011-03-17 2015-10-06 Evolution Technologies Inc. Bath chair
WO2012136768A1 (en) * 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CN105797140B (zh) 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
WO2013040501A1 (en) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
KR101828828B1 (ko) 2011-10-24 2018-03-29 할로자임, 아이엔씨 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2020002017A1 (en) 2018-06-28 2020-01-02 Konux Gmbh Planning of maintenance of railway
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US10796453B1 (en) 2019-06-28 2020-10-06 GM Cruise Holdings, LLC Vehicle sensor calibration system using dynamic scene
US20230000376A1 (en) 2019-12-02 2023-01-05 Binah.Ai Ltd System and method for physiological measurements from optical data

Also Published As

Publication number Publication date
IL233192A0 (en) 2014-07-31
US20230287381A1 (en) 2023-09-14
US20200318091A1 (en) 2020-10-08
DK2797622T3 (en) 2017-01-16
AU2017245352B2 (en) 2019-08-01
EA030252B1 (ru) 2018-07-31
IL298330A (en) 2023-01-01
US12018298B2 (en) 2024-06-25
IL274798B (en) 2021-03-25
US20230295593A1 (en) 2023-09-21
US20210284985A1 (en) 2021-09-16
US12110520B2 (en) 2024-10-08
JP6067746B2 (ja) 2017-01-25
NZ720075A (en) 2020-03-27
SI3130347T1 (sl) 2020-02-28
US12195773B2 (en) 2025-01-14
US12049652B2 (en) 2024-07-30
US12037618B2 (en) 2024-07-16
BR112014016195A2 (pt) 2020-10-27
SG10201604470TA (en) 2016-07-28
WO2013102144A8 (en) 2013-08-29
EA201400772A1 (ru) 2015-07-30
ES2749620T3 (es) 2020-03-23
MX2014007966A (es) 2014-10-17
US11952600B2 (en) 2024-04-09
US20230212547A1 (en) 2023-07-06
US20240026328A1 (en) 2024-01-25
US20240026327A1 (en) 2024-01-25
US12077791B2 (en) 2024-09-03
US20230295592A1 (en) 2023-09-21
EP3130347B1 (en) 2019-09-18
HK1202814A1 (zh) 2015-10-09
US12104184B2 (en) 2024-10-01
EP2797622A2 (en) 2014-11-05
US20240318158A1 (en) 2024-09-26
US20250197834A1 (en) 2025-06-19
US20250197832A1 (en) 2025-06-19
CY1122532T1 (el) 2021-01-27
IL317266A (en) 2025-01-01
US12054758B2 (en) 2024-08-06
EP2797622B1 (en) 2016-10-12
US12123035B2 (en) 2024-10-22
IL233192B (en) 2020-06-30
CN104244968A (zh) 2014-12-24
US12264345B1 (en) 2025-04-01
IL280949B (en) 2022-12-01
JP2015504666A (ja) 2015-02-16
ES2609582T3 (es) 2017-04-21
US9447401B2 (en) 2016-09-20
US20210277376A1 (en) 2021-09-09
US20240002825A1 (en) 2024-01-04
IL274798A (en) 2020-07-30
US20250154488A1 (en) 2025-05-15
PT3130347T (pt) 2019-12-10
CA2861919C (en) 2019-04-02
US11066656B2 (en) 2021-07-20
PL3130347T3 (pl) 2020-04-30
RS59703B1 (sr) 2020-01-31
CN104244968B (zh) 2017-07-25
CA2861919A1 (en) 2013-07-04
IL280949A (en) 2021-04-29
US12091692B2 (en) 2024-09-17
NZ626126A (en) 2016-06-24
AU2012362141A1 (en) 2014-07-10
US20230357739A1 (en) 2023-11-09
WO2013102144A3 (en) 2014-02-06
WO2013102144A2 (en) 2013-07-04
US10865400B2 (en) 2020-12-15
US12371685B2 (en) 2025-07-29
SMT201900630T1 (it) 2020-01-14
DK3130347T3 (da) 2019-10-14
SG11201403714TA (en) 2014-07-30
MX361727B (es) 2018-12-14
US20200255814A1 (en) 2020-08-13
US20240209337A1 (en) 2024-06-27
US20240002826A1 (en) 2024-01-04
IL280949B2 (en) 2023-04-01
US20230151346A1 (en) 2023-05-18
US20230250409A1 (en) 2023-08-10
US20250197836A1 (en) 2025-06-19
JP6422933B2 (ja) 2018-11-14
IL298330B1 (en) 2025-03-01
HUE047849T2 (hu) 2020-05-28
US20250197833A1 (en) 2025-06-19
US20250051747A1 (en) 2025-02-13
EP3130347A1 (en) 2017-02-15
US12104185B2 (en) 2024-10-01
JP2017112999A (ja) 2017-06-29
US20250197835A1 (en) 2025-06-19
AU2017245352A1 (en) 2017-11-02
US20160362670A1 (en) 2016-12-15
MX2018012394A (es) 2020-09-02
AU2012362141B2 (en) 2017-09-21
US20130302275A1 (en) 2013-11-14
HRP20192249T1 (hr) 2020-03-06
US11041149B2 (en) 2021-06-22
US12152262B2 (en) 2024-11-26
US20240011008A1 (en) 2024-01-11
EA030252B9 (ru) 2021-09-08
US12060590B2 (en) 2024-08-13
US20140178330A9 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
IL274798B (en) Ph20 polypeptide variants, formulations and uses thereof
IL260045B (en) Polypeptide structures and their uses
ZA201207331B (en) Concentrated protein formulations and uses thereof
IL227625A0 (en) Nanoparticle compounds, their formulations, and their use
IL237287A0 (en) Antibody compositions and their uses
HRP20181589T1 (hr) Pegilirani apelin i njegova upotreba
ZA201301160B (en) Asparaginase from basidiomycetes
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
EP2766183A4 (en) IRON FIBER COMPOSITION, PREPARATION THEREOF AND USES THEREOF
PL2635159T3 (pl) Zagłówek
ZA201500518B (en) Shampoo composition
GB201208384D0 (en) Vesicular formulations, uses and methods
GB201113314D0 (en) Formulations and processes
GB201103769D0 (en) Cosmetic formulations
GB201103767D0 (en) Cosmetic formulations
GB201222343D0 (en) Novel fast-disolving lactase solid dosage form